Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Events

08 Dec 2026 - 10 Dec 2026
25 Jan 2027 - 28 Jan 2027

AI Models Use Routine Blood Tests and Health Records to Predict Cancer Risk

By HospiMedica International staff writers
Posted on 29 Oct 2026

Cancer screening programs cover only certain cancers and often rely on broad eligibility criteria, limiting individualized risk assessment across multiple cancer types. More...

Routine health data, including blood tests and clinical history, may provide additional signals for personalized risk stratification. New findings show that machine learning models can use these data to identify people at higher risk of several common cancers.

Researchers from the Else Kröner Fresenius Center (EKFZ) for Digital Health at TU Dresden and collaborating institutions developed machine learning models to predict risk across 20 common cancers. The work also included PRE-Screen, a toolbox designed to allow artificial intelligence agents based on large language models to run the risk models consistently. The models incorporated a broad range of routine and advanced health information, including medical history, lifestyle factors, blood test results, genetic data, and metabolomic data.

The international study analyzed data from 463,620 UK Biobank participants who were followed for approximately 18 years, during which 57,055 developed cancer. The models were also evaluated in participants from Scotland and Wales, 42,036 people enrolled in the U.S. All of Us Research Program, and more than 3 million people from Japan’s JMDC database. To reduce the potential influence of cancers that were already present but undiagnosed, cases diagnosed within the first year were excluded from the relevant prediction models.

Overall, the machine learning models outperformed traditional statistical approaches, although predictive performance varied by cancer type. For a combined outcome covering cancers that could be predicted from routine clinical data, the models achieved an area under the receiver operating characteristic curve of 0.83 at 15 years.

Performance was particularly strong for lung, esophageal, and liver cancers but more limited for ovarian, breast, and cervical cancers. For acute myeloid leukemia and multiple myeloma, predictive performance declined over longer time periods, suggesting that some stronger short-term predictions may reflect early signs of cancer that was already present but had not yet been diagnosed.

Much of the predictive information came from routine blood tests and clinical history. Blood tests continued to add predictive value for cancers diagnosed more than five years later, while genetic and metabolomic data provided only a small further improvement. The findings were presented at ESMO Congress 2026 under the abstract “Development and validation of a machine-learning-toolbox for autonomous multicancer risk stratification from routine clinical data.” Because the study analyzed existing data retrospectively, further research is needed to establish whether the approach improves earlier diagnosis or outcomes.

“For selected cancers, these models could serve as a low-cost pre-screening step using data already available in routine care. Existing screening programmes cover only certain cancers and often use broad eligibility criteria, rather than assessing each person’s individual risk,” said lead author Dr. Paul-Henry Koop, Else Kröner Fresenius Center for Digital Health, TU Dresden, Germany. 

“Cancer types differ substantially in their carcinogenic mechanisms and in how strongly their risk factors and precursor conditions are captured in routine data. A positive flag should therefore trigger minimally invasive testing first,” added Dr. Koop.

Related Links
EKFZ for Digital Health
ESMO


Gold Member
12-Channel ECG
CM1200B
Hand-held Hemoglobin Analyzer
DiaSpect Tm
Glucose Meter
StatStrip®
Wound Irrigation Solution
Prontosan®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Design-science framework integrating CML and LLM pipelines for supply chain risk evaluation. (Gupta I, Konduru H, Correa S, et al. A causal analytics approach for interpretable supply chain risk and supplier performance evaluation. Supply Chain Analytics, 2026. doi:10.1016/j.sca.2026.100248)

Causal AI Tool Withholds Ovarian Cancer Treatment Recommendations When Evidence Insufficient

Ovarian cancer treatment often requires individualized decisions, particularly when available patient data do not clearly favor one therapeutic approach. However, artificial intelligence (AI) systems may... Read more

Patient Care

view channel
Image: A view inside the custom virtual reality environment used in the study: a calm room with a teddy bear, soft colors and large windows looking out over the sea. (Image Credit: Walaa S. Abu Rukbah et al., Virginia Commonwealth University; CC-BY 4.0, https://creativecommons.org/licenses/by/4.0/)

Virtual Reality Program May Reduce Anxiety Before Pediatric Surgery

Presurgery anxiety affects an estimated 50% to 75% of children undergoing surgery and can complicate anesthesia induction, increase postoperative pain, and prolong recovery. Sedation is often used to manage... Read more

Medical Imaging

view channel
Image: Overview of the study design, including participant recruitment, multimodal neuroimaging analysis, stage- and cognition-informed feature selection, and development and validation of the DBFG-Net model. CKD-CI, CKD with cognitive impairment; CKD-NCI, CKD without cognitive impairment; HCs, healthy controls; CBF, cerebral blood flow; DBFG-Net, Dual-Branch Feature-Gated Network. (Photo courtesy of Wenbo Yang and Lijun Song, Capital Medical University)

AI Combines Brain Imaging Features to Identify Cognitive Impairment in CKD

Chronic kidney disease (CKD) can affect multiple organs, including the brain, with cognitive impairment emerging as a common complication. Changes in executive function, attention, and memory can reduce... Read more

Health IT

view channel
Image Credit: Shutterstock

Telemonitoring Program Improves Quality of Life After Heart Failure Discharge

Heart failure is a chronic condition associated with high mortality, frequent hospitalizations, and reduced quality of life. Patients face particularly high risks of readmission and death after discharge,... Read more

Point of Care

view channel
Image: Jessica Ramella-Roman, professor of biomedical engineering at Florida International University, holding the PPRIM (Portable Preterm Imaging) device designed to detect early signs of preterm labor risk. (Photo courtesy of Florida International University)

Handheld Imaging Device May Help Identify Preterm Birth Risk Earlier

Preterm birth, defined as delivery before 37 weeks of pregnancy, can lead to serious neonatal complications, including neurological, developmental, and respiratory problems. However, identifying pregnancies... Read more

Business

view channel
Image: Stryker has acquired ZuriMED, adding the FiberLocker System, a rotator cuff augmentation technology designed to strengthen repairs, to its Sports Medicine portfolio. (Photo courtesy of ZuriMED)

Stryker Completes Acquisition to Broaden Shoulder Surgery Offerings

Stryker (Portage, MI, USA) has completed its acquisition of ZuriMED (Zurich, Switzerland), a privately held developer of the FiberLocker System, expanding its Sports Medicine portfolio with a commercialized... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.